Nomura Asset Management CO LTD Biotechnology

Nomura Asset Management CO LTD

$31.8 Billion
Q3 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
REGN Regeneron Pharmaceuticals, Inc.	$79.3B	$90.4 Million 0.28% of portfolio	86,004	Q3 2024 Added 4.49%
VRTX Vertex Pharmaceuticals Inc	$120B	$72 Million 0.23% of portfolio	154,894	Q3 2024 Added 4.61%
BMRN Biomarin Pharmaceutical Inc	$12.5B	$34.1 Million 0.11% of portfolio	485,609	Q3 2024 Added 29.52%
ALNY Alnylam Pharmaceuticals, Inc.	$30.3B	$23.5 Million 0.07% of portfolio	85,445	Q3 2024 Added 7.75%
UTHR United Therapeutics Corp	$17.3B	$9.19 Million 0.03% of portfolio	25,637	Q3 2024 Reduced 10.19%
MRNA Moderna, Inc.	$15.9B	$7.64 Million 0.02% of portfolio	114,335	Q3 2024 Added 1.45%
INCY Incyte Corp	$15.4B	$5.09 Million 0.02% of portfolio	76,955	Q3 2024 Added 14.38%
ARGX Argenx Se	$35.3B	$3.75 Million 0.01% of portfolio	6,907	Q2 2024 Reduced 16.32%
TECH Bio Techne Corp	$2.95B	$3.64 Million 0.01% of portfolio	45,550	Q3 2024 Added 11.16%
RPRX Royalty Pharma PLC	$11B	$2.88 Million 0.01% of portfolio	101,642	Q2 2024 Reduced 1.09%
ASND Ascendis Pharma A/S	$7.83B	$2.69 Million 0.01% of portfolio	18,000	Q3 2024 Added 42.53%
NVO Novo Nordisk A S	$244B	$2.45 Million 0.01% of portfolio	20,538	Q4 2023 Reduced 17.78%
ARVN Arvinas, Inc.	$1.02B	$2.24 Million 0.01% of portfolio	90,870	Q3 2024 Added 36.35%
BPMC Blueprint Medicines Corp	$5.76B	$2.09 Million 0.01% of portfolio	22,557	Q3 2024 Added 13.83%
DNLI Denali Therapeutics Inc.	$3.12B	$1.89 Million 0.01% of portfolio	65,033	Q3 2024 New
COGT Cogent Biosciences, Inc.	$539M	$488,000 0.0% of portfolio	45,206	Q3 2024 New
RXRX Recursion Pharmaceuticals, Inc.	$1.29B	$371,000 0.0% of portfolio	56,310	Q1 2024 Added 21.44%
LEGN Legend Biotech Corp	$5.81B	$360,000 0.0% of portfolio	7,400	Q1 2024 Added 29.82%
RVMD Revolution Medicines, Inc.	$3.96B	$93,000 0.0% of portfolio	2,064	Q3 2024 Reduced 22.26%
RARE Ultragenyx Pharmaceutical Inc.	$3.15B	$92,000 0.0% of portfolio	1,669	Q3 2024 New
PCVX Vaxcyte, Inc.	$5.33B	$92,000 0.0% of portfolio	806	Q3 2024 New
JAZZ Jazz Pharmaceuticals PLC	$7.68B	$64,000 0.0% of portfolio	583	Q2 2024 Reduced 96.43%
EXEL Exelixis, Inc.	$11.2B	$39,000 0.0% of portfolio	1,520	Q2 2023 Added 80.95%
ETNB 89bio, Inc.	$365M	$0 0.0% of portfolio	0	Q3 2024 New
ADMA Adma Biologics, Inc.	$3.66B	$0 0.0% of portfolio	0	Q3 2024 New
APLS Apellis Pharmaceuticals, Inc.	$3.79B	$0 0.0% of portfolio	0	Q3 2024 New
RNA Avidity Biosciences, Inc.	$1.71B	$0 0.0% of portfolio	0	Q3 2024 New
BNTX Bio N Tech Se	$28.5B	$0 0.0% of portfolio	0	Q3 2024 New
BBIO Bridge Bio Pharma, Inc.	$4.12B	$0 0.0% of portfolio	0	Q3 2024 New
CLDX Celldex Therapeutics, Inc.	$1.22B	$0 0.0% of portfolio	0	Q3 2024 New
CRNX Crinetics Pharmaceuticals, Inc.	$2.98B	$0 0.0% of portfolio	0	Q3 2024 New
CYTK Cytokinetics Inc	$4.5B	$0 0.0% of portfolio	0	Q3 2024 New
DAWN Day One Biopharmaceuticals, Inc.	$929M	$0 0.0% of portfolio	0	Q3 2024 New
GMAB Genmab A/S	$13.2B	$0 0.0% of portfolio	0	Q3 2024 New
IDYA Ideaya Biosciences, Inc.	$1.27B	$0 0.0% of portfolio	0	Q3 2024 New
IMVT Immunovant, Inc.	$3.55B	$0 0.0% of portfolio	0	Q3 2024 New
INSM Insmed Inc	$10B	$0 0.0% of portfolio	0	Q3 2024 New
NTLA Intellia Therapeutics, Inc.	$998M	$0 0.0% of portfolio	0	Q3 2024 New
IONS Ionis Pharmaceuticals Inc	$5.35B	$0 0.0% of portfolio	0	Q3 2024 New
IOVA Iovance Biotherapeutics, Inc.	$1.23B	$0 0.0% of portfolio	0	Q3 2024 New
KRYS Krystal Biotech, Inc.	$4.34B	$0 0.0% of portfolio	0	Q3 2024 New
LBPH Longboard Pharmaceuticals, Inc.	$815M	$0 0.0% of portfolio	0	Q3 2024 New
MDGL Madrigal Pharmaceuticals, Inc.	$5.24B	$0 0.0% of portfolio	0	Q3 2024 New
MRUS Merus N.V.	$2.06B	$0 0.0% of portfolio	0	Q3 2024 New
MIRM Mirum Pharmaceuticals, Inc.	$1.57B	$0 0.0% of portfolio	0	Q3 2024 New
MLTX Moon Lake Immunotherapeutics	$2.14B	$0 0.0% of portfolio	0	Q3 2024 New
NRIX Nurix Therapeutics, Inc.	$999M	$0 0.0% of portfolio	0	Q3 2024 New
NUVL Nuvalent, Inc.	$3.79B	$0 0.0% of portfolio	0	Q3 2024 New
OLMA Olema Pharmaceuticals, Inc.	$248M	$0 0.0% of portfolio	0	Q3 2024 New
PLRX Pliant Therapeutics, Inc.	$700M	$0 0.0% of portfolio	0	Q3 2024 New

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nomura Asset Management CO LTD, based on Form 13F filings with the SEC.

News

Stay updated on Nomura Asset Management CO LTD with notifications on news.